FDA Accepts NDA Submission for Acoramidis in ATTR-CM

The FDA's acceptance of the NDA for acoramidis in ATTR-CM was announced on February 05, 2024 and assigns a November 2024 PDUFA for the agent.

Related Keywords

,Ahmad Masri ,Bridgebio Pharma ,Isabelle Lousada ,Drug Administration ,Amyloidosis Research Consortium ,Bio Pharma Incorporated ,New Drug Application ,Prescription Drug User Fee Act ,Amyloidosis Research ,Transthyretin Amyloid ,Acoramidis Ole Data ,